7107da6d-83c9-47af-bbf5-c677e50dcfad
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 41.9493497604381
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.300
- E2F_TARGETS+0.260
- HEDGEHOG_SIGNALING+0.240
- MYC_TARGETS_V2+0.230
- IL6_JAK_STAT3_SIGNALING+0.220
- ALLOGRAFT_REJECTION+0.180
- G2M_CHECKPOINT+0.160
- KRAS_SIGNALING_DN+0.160
- PANCREAS_BETA_CELLS+0.160
- MYC_TARGETS_V1+0.130
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.440
- INTERFERON_ALPHA_RESPONSE-0.420
- OXIDATIVE_PHOSPHORYLATION-0.400
- HYPOXIA-0.380
- P53_PATHWAY-0.380
- FATTY_ACID_METABOLISM-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- APOPTOSIS-0.300
- ADIPOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_1334_T1_RNA | — | C | 0.772 |
| 2 | SRR8518135 | — | D | 0.747 |
| 3 | TCGA-BB-4217-01A-11R-2081-07 | — | — | 0.746 |
| 4 | SRR934973 | — | — | 0.746 |
| 5 | BS_N4B1SZZH | medulloblastoma | — | 0.743 |
| 6 | MNG1001 | — | — | 0.734 |
| 7 | SRR12475135 | — | — | 0.732 |
| 8 | C3L-02616 | — | cohortMD1 | 0.728 |
| 9 | BS_44A3ES23 | medulloblastoma | — | 0.725 |
| 10 | BS_JT82QGXF | medulloblastoma | — | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.180 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |